Dermatology Times
MARCH 9, 2024
The international observational study aims to understand how moderate to severe AD affects children under 12 years of age, particularly in terms of height, weight, and BMI.
CAMEO College - Esthetics
MARCH 9, 2024
Taking care of your skin goes beyond just surface-level aesthetics; it can deeply impact your mental well-being. By establishing a. The post The Power Between Your Skincare Routine and Mental Health first appeared on Cameo College of Essential Beauty.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dermatology Times
MARCH 9, 2024
Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach.
Lipgloss and Aftershave
MARCH 9, 2024
Skin by Tatum in Miami offers a $4,000 VIP Celebrity facial. Let’s get into it! It’s four hours long and incorporates four different modalities. It also includes the infusion of cutting-edge, rejuvenating products that will blow your mind! This is the brainchild of Tatum Fritts, founder of Skin By Tatum who loves using technology in her treatments. Huge thank you to The Jet Plasma Pen for sponsoring this article so that we can bring you the story of Skin By Tatum’s $4,000 VIP Celebrity Facial!
Dermatology Times
MARCH 9, 2024
Dermatologists are able to connect pediatric patients to psychology clinicians for multidisciplinary care under one roof.
The Dermatology Digest
MARCH 9, 2024
Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the role that abrocitinib (Cibinqo, Pfizer) and upadacitinib (Rinvoq, AbbVie) play in treating patients with atopic dermatitis (AD). More Conference Coverage CSU Is for You Adam Friedman, MD Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, offers up advice on how to work up and treat pa
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
The Dermatology Digest
MARCH 9, 2024
Remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase (BTK) inhibitor, bested placebo in patients with moderate to severe hidradenitis suppurativa (HS), according to new data presented at the American Academy of Dermatology’s 2024 annual meeting in San Diego, CA. B cells and plasma cells are involved in HS lesions, and BTK plays a role in the B-cell signaling path.
Dermatology Times
MARCH 9, 2024
Iltefat Hamzavi, MD, reviews late-breaking data at AAD on upadacitinib as monotherapy.
The Dermatology Digest
MARCH 9, 2024
The biosimilars are here with even more coming down the pike. Mark Lebwohl, MD, Dean for Clinical Therapeutics and Waldman Professor and Chairman of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City, explains how he is using biosimilars in his practice during a talk at the American Academy of Dermatology’s annual meeting in San Diego.
Dermatology Times
MARCH 9, 2024
Catch up on coverage from the second day of the 2024 American Academy of Dermatology Annual Meeting.
The Dermatology Digest
MARCH 9, 2024
Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, discusses the role that abrocitinib (Cibinqo, Pfizer) and upadacitinib (Rinvoq, AbbVie) play in treating patients with atopic dermatitis (AD). More Conference Coverage CSU Is for You Adam Friedman, MD Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, offers up advice on how to work up and treat pa
Dermatology Times
MARCH 9, 2024
Christopher Bunick, MD, PhD, provides tips for the general dermatologist to treat ichthyosis and shares data on TMB-001 in development for ichthyosis.
The Dermatology Digest
MARCH 9, 2024
Nada Elbuluk, MD, an Associate Professor in the Department of Dermatology at the University of Southern California’s (USC) Keck School of Medicine in Los Angeles and the Founder and Director of the USC Skin of Color Center and Pigmentary Disorders Program, shares highlights from the 20th Annual Skin of Color Society Symposium, Pathways to Equity: Advancing Advocacy, Research, and Clinical Excellence, which she co-chaired.
Dermatology Times
MARCH 9, 2024
The American Acne and Rosacea Society welcomed Del Rosso as its new president and he shared key takeaways from his AAD sessions.
The Dermatology Digest
MARCH 9, 2024
Chronic hand eczema (CHE) symptoms can take a dramatic toll on patients’ quality of life. Jonathan Silverberg, MD, PhD, MPH, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, discusses the need for a comprehensive treatment approach for CHE. More Conference Coverage CSU Is for You Adam Friedman, MD Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC
Dermatology Times
MARCH 9, 2024
In an AAD late-breaking research session, Joel Gelfand, MD, MSCE, FAAD, presented in-depth results of the LITE Study.
The Dermatology Digest
MARCH 9, 2024
Johnson & Johnson’s investigative oral interleukin (IL)-23 blocker, JNJ-2113, maintains skin clearance in moderate-to-severe plaque psoriasis through one year, according to data from the long-term extension FRONTIER 2 study presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. In FRONTIER 2, JNJ-2113 maintained high rates of skin clearance through 52 weeks in adults with moderate-to-severe plaque Psoriasis.
Dermatology Times
MARCH 9, 2024
Keep up with the latest headlines in dermatology from the past week, including benzene findings reported by independent laboratory Valisure, Galderma's plans for a $2.3 billion IPO on the Swiss stock exchange, and more.
The Dermatology Digest
MARCH 9, 2024
Upadacitinib (Rinvoq, AbbVie) 15mg or 30mg cools vexing nighttime itch in people with moderate-to-severe atopic dermatitis (AD), according to new research presented at the American Academy of Dermatology’s annual meeting in San Diego. When compared with AD patients taking placebo, patients with AD who were treated with treated with upadacitinib spent more time with no/minimal nighttime itch and no/minimal sleep disturbance, the study showed.
The Dermatology Digest
MARCH 9, 2024
Seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature, according to new data presented at the American Academy of Dermatology annual meeting in San Diego, CA. Researchers analyzed RNA sequencing via noninvasive tape-stripping techniques on facial lesions from 27 untreated patients with seborrheic dermatitis and the facial skin of 18 healthy controls.
The Dermatology Digest
MARCH 9, 2024
Use of a water-based face cream with novel natural moisturizing factor and lipids (Hydro Boost Water Cream, Neutrogena) produces lasting improvements in skin hydration and barrier function, according to two preclinical and two clinical studies presented at the 2024 American Academy of Dermatology’s annual meeting in San Diego. When skin explants were treated with the moisturizing cream and assessed for changes in barrier- and hydration-relevant gene expression in an ex-vivo gene and protein expr
The Dermatology Digest
MARCH 9, 2024
Apremilast (Otzela, Amgen) can improve symptoms in patients with moderate to severe palmoplantar pustulosis who had an inadequate response to topical therapy, according to a late-breaking Phase 3 study presented at the annual meeting of the American Academy of Dermatology in San Diego, CA. The randomized, placebo-controlled, double-blind study included 176 patients who received apremilast (n=88) or placebo (n=88) for 16 weeks.
Expert insights. Personalized for you.
90 
Let's personalize your content